Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

CNBC

Center

Mixed Factuality

Individual: Roberts Family

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.

Benzinga

Center

High Factuality

Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk’s (NYSE:NVO) Ozempic. This comes a day ahead of the company announcing its first-quarter earnings of 2024. What Happened: The Danish Medicines Agency disclosed on Wednesday that starting from Nov. 25, patients will be prescribed less expensive drugs before resorting to GLP-…

Bloomberg

Lean Left

Mixed Factuality

Individual: Michael Bloomberg

Private Equity: The Vanguard Group

Ozempic Frenzy Gives Novo Nordisk ‘Superpowers’ in Denmark

Devdiscourse

Center

High Factuality

Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast

Operating profit growth this year is now seen at between 22% and 30% in local currencies, slightly up from its previous forecast of 21% to 29%. Novo reported first-quarter earnings before interest and taxation (EBIT) of 31.8 billion Danish crowns, above the 29 billion forecast by analysts in a LSEG poll this week.

Forbes

Center

Mixed Factuality

Individual: Forbes Family (Publishers)

Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy

Sales of Novo’s popular weight loss drug Wegovy more than doubled from this time last year, the company said.